A client with CKD and type 2 diabetes takes finerenone. Which action should the nurse take first?
Chart/Exhibit
Choose your responses, then check the answer.
Explanation
Hyperkalemia and a strong CYP3A4 inhibitor create immediate finerenone safety concerns, so the dose and interaction require clarification before administration.
Quick answer Stop for high potassium plus a strong interaction.
Why this is correct Finerenone can cause hyperkalemia and is contraindicated with strong CYP3A4 inhibitors; potassium and renal function guide interruption and restart.
Easy analogy or mental picture Think of medication safety as a control panel: identify the dangerous signal, change the correct control, and verify the response.
Memory hook Cue, action, response, reassessment.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving the continuing indication.
Why the other choices are wrong Options that delay escalation, ignore a contraindication, or change therapy without authorization do not close the safety loop.
References
1DailyMed: KERENDIA (finerenone)Potassium and eGFR assessment, hyperkalemia monitoring, dose interruption, and interaction safety
Medication safety reviewVerify the indication, current assessment, laboratory trend, timing, interactions, authorized action, and measurable follow-up.